Barbara Adamo

Grupo de investigación

Genómica traslacional y terapias dirigidas en tumores sólidos Accredited researcher (R3A)

adamo@clinic.cat 0000-0001-7129-8156

Publicaciones destacadas

Gene expression profiles of breast cancer metastasis according to organ site

Autores:
Braso-Maristany, Fara; Pare, Laia; Chic, Nuria; Martinez-Saez, Olga; Pascual, Tomas;

(...)

Adamo, Barbara; Moreno, Reinaldo; Vidal, Maria; Munoz, Montserrat; Prat, Aleix.

Referencia: Molecular Oncology 2022.
Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy: ER activity in pre-menopausal HR+ breast cancer during CT

Autores:
Chic, Nuria; Schettini, Francesco; Braso-Maristany, Fara; Sanfeliu, Esther; Adamo, Barbara;

(...)

Munoz, Montserrat; Perou, Charles M; Pascual, Tomas; Bellet, Meritxell; Prat, Aleix.

Referencia: Ebiomedicine 2021.
Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptor-Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2-Based Therapy

Autores:
Pascual, Tomas; Fernandez-Martinez, Aranzazu; Tanioka, Maki; Dieci, M Vittoria; Pernas, Sonia;

(...)

Pare, Laia; Galvan, Patricia; Carey, Lisa A; Perou, CharlesM; Prat, Aleix.

Referencia: Clinical Cancer Research 2021.
COVID-19 pandemic impact in newly diagnosed breast cancer patients (BCP) at a third level hospital

Autores:
Sacoto, MCG; Moreno, R; Rodríguez, A; Núñez-Manchón, E; Bargalló, X;

(...)

Mollà, M; González, GO; Gonzalez-Farre, B; Font, JF; Vidal-Sicart, S.

Referencia: Annals Of Oncology 2021.
Subsequent therapies after progressing to CDK4/6 inhibition (CDK4/6i) in hormone receptor positive/HER2 negative (HR+/HER2-) advanced breast cancer (ABC)

Autores:
Laguna, JC; Hernandez, AR; Chic, N; Adamo, B; Vidal, M;

(...)

Galván, P; Díez-Guardia, V; Pascual, T; Torres, ES; Gonzalez-Farre, B.

Referencia: Annals Of Oncology 2021.
CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data

Autores:
Martínez-Sáez, O; Hernandez, AR; Chic, N; Laguna, JC; Vidal, M;

(...)

Schettini, F; Parrilla, L; Ruano, Y; Torres, ES; Gonzalez-Farre, B.

Referencia: Annals Of Oncology 2021.
Circulating tumor DNA dynamics in advanced breast cancer treated with CDK4/6 inhibition and endocrine therapy

Autores:
Martinez-Saez, Olga; Pascual, Tomas; Braso-Maristany, Fara; Chic, Nuria; Gonzalez-Farre, Blanca;

(...)

Salvador, Fernando; Ciruelos, Eva M; Faull, Iris; Odegaard, Justin I; Prat, Aleix.

Referencia: Npj Breast Cancer 2021.
Molecular characterization of advanced breast cancer according to site of metastasis

Autores:
Braso-Maristany, Fara; Pare, Laia; Chic, Nuria; Martinez-Saez, Olga; Pascual, Tomas;

(...)

Adamo, Barbara; Moreno, Reinaldo; Vidal, Maria; Munoz, Montserrat; Prat, Aleix.

Referencia: Cancer Research 2021.
Solti-1502 aRIANNA: Targeting PAM50 HER2-enriched intrinsic subtype with enzalutamide in hormone receptor-positive/HER2-negative metastatic breast cancer

Autores:
Oliveira, Mafalda; Pernas, Sonia; Margeli, Mireia; Blanch, Salvador; Adamo, Barbara;

(...)

Prat, Aleix; Pascual, Tomas; Ferrero-Cafiero, Juan M; Villagrasa, Patricia; Manso, Luis.

Referencia: Cancer Research 2021.
HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis

Autores:
Schettini, Francesco; Pascual, Tomas; Conte, Benedetta; Chic, Nuria; Braso-Maristany, Fara;

(...)

Osborne, C Kent; Pernas, Sonia; Perou, Charles M; Carey, Lisa A; Prat, Aleix.

Referencia: Cancer Treatment Reviews 2020.

Proyectos destacados

Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

Investigador/a principal: Aleix Prat Aparicio

Duración: 15/09/2019 - 14/09/2022
Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer

Investigador/a principal: Aleix Prat Aparicio

Código: INT_BCN_Catalyst_18

Duración: 01/03/2019 - 28/02/2023
Caracterización de los linfocitos T CD8+PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched

Duración: 01/01/2019 - 01/01/2020
FIS-ISCIII: Análisis de eficacia de inhibidores cDK4/6 en combinación con tratamiento hormonal en base al subtipo intrínseco y marcadores de inmunidad

Duración: 01/01/2018
Convocatòria d'ajuts per donar suport a les activitats dels grups de recerca SGR 2017-2019

Investigador/a principal: FAya

Duración: 01/01/2017 - 01/01/2019

Barbara Adamo

Grupo de investigación

Publicaciones destacadas

Molecular characterization of advanced breast cancer according to site of metastasis

Proyectos destacados

Treatment of advanced breast cancer with adoptive therapy of CD3+/PD1+ tumor infiltrating lymphocytes

Targeting the HER2-enriched phenotype in hormone receptor-positive breast cancer

Caracterización de los linfocitos T CD8+PD1+ en cáncer de mama avanzado receptor hormonal-positivo con un fenotipo agresivo HER2-enriched

FIS-ISCIII: Análisis de eficacia de inhibidores cDK4/6 en combinación con tratamiento hormonal en base al subtipo intrínseco y marcadores de inmunidad

Convocatòria d'ajuts per donar suport a les activitats dels grups de recerca SGR 2017-2019

Suscríbete a la Newsletter del Clínic